In the work, we have reviewed here, the chromatin remodeling enzyme BRG1 and its breast cancer-specific effects on lipid metabolism are an attractive target for breast cancer therapy. Our work establishes that one part of the anti-cancer mechanism of BRG1-targeted drugs is an effect on fatty acid synthesis decreasing proliferation. Unlike genetic alterations, epigenetic mechanisms are reversible, promising gentler therapies without permanent off-target effects at distant sites.
